Objective: To investigate a potential role for obestatin in humans by examining response to a fixed energy meal. Context: A new anorectic peptide hormone, obestatin has recently been isolated from rat stomach. The significance of this peptide in humans is unknown. Study design: Case-control study. Setting: Hospital-based study. Patients: Nine healthy controls, nine morbidly obese subjects and eight post-gastrectomy subjects. Intervention: Subjects attended after an overnight fast and were given a fixed energy meal (1550 kJ). Main outcome measure: The response of obestatin to a meal in the different groups. Results: Fasting obestatin was significantly lower in obese subjects as compared to lean subjects (27.874 vs 17.272 pg/ml, P ¼ 0.03). Obestatin was also decreased in gastrectomy subjects but this did not reach statistical significance (27.874 vs 21.973 pg/ml, P ¼ 0.3). Obestatin did not change significantly from baseline in response to the meal. Lean and obese subjects had a similar obestatin/ghrelin ratio (0.0470.003 vs 0.0570.009, P ¼ 0.32), but this was higher in the gastrectomy group (0.0470.003 vs 0.170.01, Po0.001). Conclusions: Obestatin does not vary significantly with a fixed energy meal, but is significantly lower in morbidly obese subjects as compared to lean subjects supporting a possible role for obestatin in long-term body weight regulation. Obestatin tended to be lower in gastrectomy subjects and their obestatin/ghrelin ratio differed from healthy controls. Hence, the expression of obestatin is altered following gastrectomy, suggesting other sites outside the stomach may also secrete obestatin.
Introduction
Levels of obesity on a global scale are reaching epidemic proportions and continue to strain national resources. Body weight regulation is a complex tightly controlled process, and peptides generated in the gut and brain appear to play an important role.
Ghrelin was discovered in 1999 1 and the subsequent discovery of its actions on appetite has since provoked widespread interest. 2, 3 The ghrelin gene is located on chromosome 3
(3p25-26) codes for a 117 amino acid peptide, prepro-ghrelin. 1 Human ghrelin is a 28 amino acid peptide that is derived from post-translational cleavage of prepro-ghrelin. Recently, Zhang et al. 4 discovered another product of the ghrelin gene called obestatin. This was isolated from rat stomach and binds to an orphan G-protein-coupled receptor GPR39, a member of the ghrelin receptor family. The receptor GPR39 is expressed in several different tissues in human and rodents including the stomach, small intestine, pituitary and hypothalamus. 4, 5 Another study found GPR39 expression in the rodent amygdala, hippocampus, auditory cortex and other brain regions but not the hypothalamus. 6 Since the original study, however, two other groups have failed to activate the GPR39 receptor with obestatin. 7, 8 Initial studies showed that obestatin has opposing effects to ghrelin. When given centrally and peripherally to mice, it resulted in decreased food intake and suppressed gastric emptying. Given chronically over 8 days, obestatin also decreased weight gain in mice, as compared to vehicle. 4 Similarly, ghrelin induces wakefulness in rodents 9 and subsequent research has shown that centrally administered obestatin increases time in non-rapid-eye-movement sleep; hence obestatin has a sleep-promoting effect. 10 However, unlike with ghrelin, fasting rodents for 48 h and then re-feeding has no effect on obestatin levels. 4 Since the original publications two groups have partially confirmed the effects of obestatin on food intake and gastric emptying, 11, 12 but two other groups have failed to replicate these findings. 13, 14 Its significance in the short-term regulation of food intake therefore remains uncertain. At present, the importance of obestatin in humans is unknown. One group has looked at obestatin in obese children and subjects with Prader-Willi syndrome (PWS) and found no significant difference between the groups. 15 It is known that plasma ghrelin levels are decreased in adults who are obese, 16 and are reduced by at least 50% in subjects with previous gastrectomy. 17 Plasma levels of obestatin in these groups are also unknown. The aim of our study was to further characterise plasma levels of the new peptide obestatin around a fixed calorie meal in lean controls, obese subjects and those with previous gastrectomy.
Methods
Healthy volunteers and obese subjects were recruited by advertisement and from a local weight management clinic. Subjects with previous gastrectomy were invited to participate from a surgical clinic database. The study was approved by the South Sefton Research Ethics Committee, Liverpool, UK (project registration number EC.05.03) and was performed in accordance with the principles of the Declaration of Helsinki. Volunteers gave written informed consent and had a normal physical examination and electrocardiogram.
Subjects
We studied nine healthy volunteers aged 25-62 (mean7 s.e.m., 41.374.2), body mass index (BMI) 18.0-27.2 (22.970.9), nine obese volunteers aged 32-50, BMI 38.4-59.5 (49.672.6) and eight post-gastrectomy volunteers aged 53-75, BMI 17.0-27.0 (24.571.4). Due to lack of normative data on obestatin in humans when the study was performed, subject numbers were based on recruitment and the minimum numbers needed in previous published work on ghrelin profiles in humans. 18 Obesity was defined as BMI430 kg/m 2 according to the criteria of the World Health
Organisation and the International Obesity Task Force. All gastrectomy subjects underwent total gastrectomy for gastric carcinoma at least 12 months previously and were in remission (all had no evidence of recurrence by gastroscopy within the last 12 months). All subjects had a truncal vagotomy as part of the procedure. The mean time between surgery and the study was 7.571.1 years (mean7s.e.m.). Details of surgery are shown in Table 1 . Gastrectomy subjects with significant bile reflux and symptoms of dumping syndrome were excluded. Subjects in all groups with ischaemic heart disease, type 2 diabetes and those aged over 75 years were excluded.
Protocol
Subjects were asked to fast and drink only water from 2100 on the night before the study, and to refrain from alcohol or strenuous exercise in the 24 h preceding the study day. Subjects attended at 0800 on each study day, when anthropometric measurements were taken. After arrival, subjects were blinded to external time cues until the end of the study. They were weighed and measured wearing light clothing and without shoes. Waist circumference was measured midway between the iliac crest and the lower border of the rib cage. Body fat percentage (BFP) was estimated by whole-body bioelectrical impedance analysis (Tanita Systems, Stokie, IL, USA). An intravenous cannula was inserted into a forearm vein and used for blood sampling. After venous cannulation, the subjects relaxed for 30 min before the start of the study protocol.
A fixed energy breakfast was given to all subjects at 0930. This consisted of 40 g cornflakes, 250 ml whole milk, 3.5 g sugar (1 sachet) and 100 ml fresh orange juice (1550 kJ, 62% carbohydrate, 13% protein and 25% fat). Subjects consumed the test breakfast within 15 min.
Blood samples were taken at baseline, 30, 60, 90, 120 min and then hourly until the end of the study. The study was completed at 1230. Samples were collected into plastic Lithium Heparin tubes containing 0.07 mg aprotonin (500 Kallikrein Inactivator Units), centrifuged immediately and then stored at À801C until assayed. At each sampling point subjects also completed a visual analogue scale (VAS) rating hunger and satiety (possible scores 0-100 mm). VAS ratings were measured by an investigator blinded to study group. Obestatin in lean, obese and gastrectomy MSB Huda et al Assays Plasma total (acylated and deacylated) ghrelin was determined in duplicate by a commercially available radioimmunoassay (Phoenix Pharmaceuticals, Belmont, CA, USA). Inter-assay and intra-assay coefficients of variation were 7.3 and 9.5%, respectively. Plasma obestatin was also determined in duplicate by a commercially available radioimmunoassay that uses 125 I-labelled bioactive obestatin as a tracer and a rabbit polyclonal antibody raised against full-length amidated human obestatin (Phoenix Pharmaceuticals). It is not known to cross-react with any gastrointestinal or pancreatic peptides. As the obestatin antibody is polyclonal, it binds to both amidated and non-amidated obestatin peptides; the measured concentrations are therefore of 'total' obestatin. Initially, pooled plasma was spiked with known concentrations of obestatin peptide and assayed. Plasma was extracted with commercially available separation columns (SEP-C 18 column Phoenix Pharmaceuticals), using 1% trifluoroacetic acid and 60% acetonitrile as buffer reagents. After extraction, the eluent was evaporated to dryness, initially using a centrifugal concentrator (Speedvac s , Thermo Fisher Scientific Inc., USA), and then lyophilised overnight in a freeze dryer. Recovery was between 77 and 85% after plasma extraction. The inter-and intra-assay coefficients of variation were 10.9 and 15.9%, respectively. Our lower limit of detection was 7.7 pg/ml.
Statistical analysis
The Statistical Package for the Social Sciences version 13.0. (SPSS, Chicago, IL, USA) was used for data analysis. Mean values are expressed as geometric means7s.e.m. Comparison between groups was performed using paired t-tests or the equivalent non-parametric tests. Within-group and group interactions with time were analysed using analysis of variance (ANOVA) for repeated measures. Total area under the curve (AUC) was calculated using the trapezoid rule. Statistical association was calculated using Pearson (r) correlation coefficients. Negative results are accompanied by 95% confidence intervals (CI) for the difference in means. Two tailed P-values were considered significant when Po0.05.
Results
Baseline characteristics are summarised in Table 2 . The lean and obese groups were well matched for age and gender, but the gastrectomy group was significantly older (41.474 vs 65.372, Po0.05). However, no significant correlation between age and fasting obestatin or fasting ghrelin was found in any of the three groups. The mean BMI in the obese group (49.673 kg/m 2 ) was significantly higher than in the lean group (22.971 kg/m 2 ). Weight, waist circumference and BFP were also higher in the obese group. There was no significant difference in BMI, weight, waist circumference, BFP or absolute fat mass in the gastrectomy group as compared to the lean group.
Fasting ghrelin levels were significantly lower in the obese group as compared to the lean group (762.1771 vs 414.3786 pg/ml, P ¼ 0.04) and lower still in the gastrectomy group (762.1771 vs 226.1762 pg/ml, Po0.0001). Ghrelin AUC data is shown in Figure 1 . There was a significant difference between lean and obese groups (42.875 vs 25.675 ng/ml/min, P ¼ 0.03) and between lean and gastrectomy groups (42.875 vs 15.174 ng/ml/min, Po0.001).
Fasting obestatin levels were also lower in the morbidly obese group (27.874 vs 17.272, P ¼ 0.03). Although they were also decreased in the gastrectomy group, this did not reach statistical significance (27.874 vs 21.973 pg/ml, P ¼ 0.3 (95% CI for difference in means À4.5 to 16.4)).
The responses of obestatin to a fixed energy meal are shown in Figure 2 . There was no significant change over time in any of the different groups (ANOVA for repeated measures Obestatin in lean, obese and gastrectomy MSB Huda et al P ¼ NS). Summary statistics for the hormone profile over time are also shown in Table 1 . The AUC for obestatin in lean subjects was significantly higher than in obese subjects (67107907 vs 43037401 pg/min/ml, P ¼ 0.03). There was however no statistically significant difference between lean and gastrectomy subjects (67107907 vs 51977802/pg/min/ ml, P ¼ 0.2 (95% CI for difference in means À4104.5 to 1078.3)).
The obestatin/ghrelin ratio was calculated at each time point but did not significantly change with time or in response to the meal in any of the three groups ( Figure 3 Hunger and satiety VAS scores in response to the test meal did not vary significantly between the three groups (ANOVA P ¼ NS). There was also no significant correlation between the AUC of hunger or satiety VAS scores with either plasma ghrelin AUC (hunger P ¼ 0.3, satiety P ¼ 0.9) or plasma obestatin AUC (hunger P ¼ 0.1, satiety P ¼ 0.4).
There was a highly significant positive correlation between obestatin and ghrelin (r ¼ 0.71, Po0.001) and significant inverse correlations between fasting obestatin and body weight (r ¼ À0.56, P ¼ 0.003), BMI (r ¼ À0.51, P ¼ 0.008), waist circumference (r ¼ À0.52, P ¼ 0.01) and absolute fat mass (r ¼ À0.51, P ¼ 0.008). These are shown in Figure 4 .
Discussion
To our knowledge, this is one of the few studies that characterises plasma obestatin levels in humans. Our study shows that plasma obestatin did not vary significantly around a fixed energy meal. This seems to correlate with the findings of Zhang et al., who found no significant change in plasma obestatin in the fasted or fed state in rodents. This is also in keeping with the only other human data available at present in obese and PWS children; Park et al. 15 did not find any significant change in baseline in obestatin after a 75 g glucose load in either group of subjects. Our study terminated at 1230 when most volunteers would have been ready for another meal and yet plasma obestatin levels did not significantly change. However, our test meal was typical of an average European-style breakfast and a larger calorie load may be needed to elicit a hormonal response. A full 24-h hormone profile around three fixed meals would help clarify this question. Our test meal was carbohydrate based and it is possible that meals of different nutrient composition may elicit a different obestatin response. Similarly, though we used identical test meals for ease of comparison, we accept that this meal may have understimulated obese subjects, and possibly over-stimulated lean and gastrectomy subjects which may have contributed to differences in obestatin response in the three groups. However, this is unlikely as hunger and satiety ratings in response to the test meal were similar in all three groups. Moreover, this would not have accounted for differences in fasting levels of obestatin within the groups.
Obestatin levels were significantly lower in the obese. Consistent with other reports, these subjects also had low plasma ghrelin levels and showed little response to meals. 16, 19 The ratio of obestatin to ghrelin also remained constant during the experiment and was not significantly different to the lean subjects. The reduction of circulating obestatin is unexpected in terms of a physiological Obestatin in lean, obese and gastrectomy MSB Huda et al obese state. Decreased obestatin in obese subjects also implies a role for obestatin in long-term body weight regulation.
Obestatin and ghrelin appeared to be positively correlated, which also suggests that expression of the ghrelin gene may regulate both of these peptides. Park et al. 15 also reported a positive correlation between obestatin and acylated ghrelin in obese and PWS children. In keeping with our observation that obestatin is reduced in obesity, there was a significant inverse correlation between obestatin and body weight, BMI and waist circumference and with absolute fat mass. Although it has not been confirmed that the GPR39 receptor is activated by obestatin, Catalan et al. 20 have recently shown that the GPR39 receptor is present in adipose tissue and that it is downregulated in obese type 2 diabetes, but interestingly not in non-diabetic obese subjects. Similar to other studies, we have shown that gastrectomy subjects have low plasma ghrelin levels. 17 Obestatin levels were also lower in gastrectomy subjects than in healthy controls though this did not reach statistical significance. Zhang et al. incubated various tissues with obestatin-specific antibodies and found that stomach extracts displaced 125 Iobestatin. They then subsequently purified the obestatin-like activities from the stomach extracts. 4 It is therefore perhaps surprising that plasma obestatin levels were not lowered further in subjects with a previous gastrectomy. It is possible however that obestatin is produced in significant quantities elsewhere in the body. We know that approximately 30% of ghrelin production has been attributed to the small intestine, 21 and obestatin may also be co-secreted from these small intestinal ghrelin cells. Furthermore, the GRP39 receptor has also been mapped to several other tissues including small intestine, lung, kidneys and heart. Of note, 125 I-obestatin binds with high affinity to the jejunum and duodenum, which indicates a high concentration of the GRP39 receptor in these tissues. 4 Intriguingly, the obestatin to ghrelin ratio was significantly higher in gastrectomy subjects than in lean or obese subjects. There may be different explanations for this. The expression of a gene may vary according to the tissue, leading to different mRNA products. Hence, the intestinal cells may express a different obestatin/ghrelin ratio to the stomach. It is possible that this is under the influence of gastric factorsFeither neural or endocrineFand these are disrupted following removal of the stomach and/or vagotomy.
Another explanation is that the post-translational modification of a peptide is altered following disruption to the normal intestinal anatomy. We know that like ghrelin, which requires acylation for many of its actions, obestatin is amidated at its C terminus. Non-amidated obestatin shows a lower binding affinity to GPR39 than amidated obestatin. 4 Again, this process may be altered following gastrectomy and/or vagotomy. This also highlights a potential weakness in our study; our assay measured 'total' obestatin, that is both amidated obestatin and non-amidated obestatin. The different concentrations of amidated and non-amidated obestatin are still unknown in these groups of subjects.
It is noteworthy that overall plasma obestatin circulates in concentrations that are between 5 and 10% of corresponding plasma ghrelin levels. These lower concentrations may suggest the actions of obestatin are more localised than ghrelin. However, the half-life of obestatin in plasma is not known and the low circulating concentrations may simply reflect vigorous breakdown in plasma.
In conclusion, we have shown that plasma obestatin levels do not vary significantly with a fixed energy meal, but are significantly lower in obese subjects as compared to lean controls, indicating a role for obestatin in long-term body weight regulation. We have also shown that whilst obestatin levels tended to be lower in gastrectomy subjects, their obestatin/ghrelin ratio differed from healthy controls, and hence the expression of obestatin may be altered following surgical disruption to normal gut anatomy.
